NanoDetection Technology

Acquired

Hill Top Research is a site-based clinical research organization for pharmaceutical and consumer products testing.

Hill Top Research

DW Healthcare Partners

By siliconindia   |  Thursday, 05 October 2023, 04:25:53 PM IST
Dassault Systemes announced that Sai Life Sciences, India’s fastest growing contract research, development, and manufacturing organization has selected Dassault Systemes solutions to enhance productivity, elevate data quality, and foster collaboration within Sai Life Sciences Research and Process Development laboratories leading to accelerated drug discovery. Sai Life Sciences is using Dassault Systèmes' industry solution experience “ONE Lab” based on the 3DEXPERIENCE platform. The solution, which leverages BIOVIA applications, helps optimise productivity, ensure data accuracy and data security, and enable seamless data accessibility and analysis. Sai Life Sciences has implemented “ONE Lab” to bolster security measures, and facilitate effortless data access and analysis. Utilizing “ONE Lab", Sai Life Sciences is creating an integrated digital platform for its research and development (R&D) and chemistry, manufacturing and controls (CMC) laboratories, effectively tackling some of the most notable challenges ailing the research in this sector, specifically associated with project implementation. The primary objectives of this selection encompass error reduction, time-saving, the promotion of sustainability practices, and the establishment of a unified, reliable source of information to facilitate multi-stakeholder collaboration spanning research, development and commercial manufacturing. "With Sai Life Sciences, we are attempting to build a brighter future for life sciences and health care research and development in the country. Our long-term vision is to redefine industry standards by combining transformative technology with unwavering commitment. This is not just about optimizing productivity and data quality; it is about setting a new benchmark for collaboration and efficiency in the industry. We are not simply innovating; we are shaping the future of research, one breakthrough at a time", said Deepak NG, Managing Director India, Dassault Systemes. "With Dassault Systemes solutions, we are ushering in a new era of research and development excellence. The integration of Dassault Systemes ‘ONE Lab’ empowers us to drive productivity, enhance data quality, and fortify data security, revolutionizing our approach to research across the entire spectrum from early-stage development to commercial manufacturing", said Dr. Damodharen, Chief Quality Officer, Sai Life Sciences. “ONE Lab” has played a pivotal role in empowering Sai Life Sciences to construct an all-encompassing digital platform for its R&D and CMC laboratories. This accomplishment involved surmounting common project implementation challenges, notably in the realm of change management. “ONE Lab” offers numerous benefits to the industry, including optimization of laboratories and knowledge utilization for accelerated time-to-market. Furthermore, it contributes to a substantial reduction in compliance risk through the standardization of processes and enhanced data quality. Additionally, the solution delivers a remarkable boost in productivity and efficiency through streamlined processes and automation, leading to a reduction in cycle time, thereby enabling real-time project tracking and expediting decision-making. Read More News :

Sai Life Sciences Selects Dassault Systemes to Accelerate Drug Discovery and Boost Clinical Research

Hyderabad,  INDIA
HYDERABAD, India, Aug.  21, 2023  (GLOBE NEWSWIRE) -- Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO) , entered its Silver Jubilee year with aplomb, surpassing its vision of supporting global innovator partners in bringing 25 new medicines to market by 2025. The company crossed this milestone two years ahead of schedule and is poised to sustain this momentum on the back of a strong portfolio of molecules at various stages of clinical development. Marking the entry into its 25th year, the Chairman Dr. K. Ranga Raju and members of the senior management inaugurated multiple new laboratories and facilities, and a grand new entrance to its 12-acre integrated R&D campus in Hyderabad. Notable among the new laboratories were a doubling of its DMPK footprint and a sizeable expansion of analytical R&D capacity for its Discovery Chemistry services. Expressing delight on the occasion, Dr. K. Ranga Raju, Founder Chairman, said, “Over the last 24 years, thanks to the trust that our clients have reposed in us, Sai Life Sciences has grown from a small lab with two fume hoods into a global CRO-CDMO providing the entire range of services along the drug discovery journey with world-class facilities across three continents and propelled by a 2,900-strong talent pool. As we look to the future, we rededicate ourselves to working with global innovator partners to accelerate a healthier future.”
The occasion also formally concluded the company’s Sai Nxt initiative, which witnessed strategic investments of over US$130 million during 2019-2023, enabling the company to augment capacity, scale up operations, expand into new geographies, grow the scientific talent base, and raise the overall bar for quality, compliance, and performance. Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, said, “In 2016, we set a vision for ourselves to support our global innovator partners in bringing 25 new medicines to life by 2025. I’m delighted to share that we’ve surpassed this goal two years ahead of schedule. There can’t be anything more gratifying for us as a company as we enter our silver jubilee year.”
The company has announced a series of initiatives as part of its 25th year celebrations culminating in August 2024, to commemorate the company’s journey, acknowledge contributions of various individuals, and engage all its stakeholders in charting a collective future. Sauri Gudlavalleti, Chief Operating Officer of Sai Life Sciences, said, “We are excited about the next phase of our growth. We will actively engage with our clients, partners, and employees to chart a journey that will enable us to meaningfully impact the future of healthcare.”
About Sai Life Sciences:
Sai Life Sciences is a full-service CRO-CDMO that works with the innovator pharma and biotech companies globally, to accelerate the discovery, development, and commercialisation of complex small molecules. The company has 2,900 employees across its facilities in India, UK and USA. Sai Life Sciences is privately held and backed by global investors, TPG Capital and HBM Healthcare Investments. https://www.sailife.com/
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8841bd0e-378a-4f69-85b2-fb08f49c59b0
Sai Life Sciences enters its Silver Jubilee year
Sai Life Sciences enters its Silver Jubilee year

Sai Life Sciences enters its Silver Jubilee year; surpasses vision of 25 commercial molecules by 2025

Author of the article:
Article content
HYDERABAD, India, Aug. 21, 2023 (GLOBE NEWSWIRE) — Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO) , entered its Silver Jubilee year with aplomb, surpassing its vision of supporting global innovator partners in bringing 25 new medicines to market by 2025. The company crossed this milestone two years ahead of schedule and is poised to sustain this momentum on the back of a strong portfolio of molecules at various stages of clinical development. Advertisement 2
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada. Exclusive articles by Kevin Carmichael, Victoria Wells, Jake Edmiston, Gabriel Friedman and others. Daily content from Financial Times, the world's leading global business publication. Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada. Exclusive articles by Kevin Carmichael, Victoria Wells, Jake Edmiston, Gabriel Friedman and others. Daily content from Financial Times, the world's leading global business publication. Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword. REGISTER TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors.

Hyderabad,  INDIA
HYDERABAD, India, June  22, 2023  (GLOBE NEWSWIRE) -- To help combat climate change, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO) , announced joining Science Based Targets initiative (SBTi), a global body enabling businesses to set ambitious emission reduction targets in line with the latest climate science. Accordingly, it has committed to set near-term company-wide emission reductions in line with climate science with the SBTi. These are 5-10-year GHG (Greenhouse gas) mitigation targets in accordance with the Paris Agreement’s aim to limit global temperature rise to 1.5°C to avoid the catastrophic impacts of climate change. Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “Sai Life Sciences has joined the SBTi to address a collective imperative. The association will help in sharpening our approach to assess the impact of climate change and develop a strategy to address it. It will also strengthen our ability to nurture an organizational culture, where each employee is mindful of every act and its impact on the environment.”
Joining the SBTi will enable Sai Life Sciences to set targets, assess progress and calibrate actions to meet its goals in a time-bound manner. It will allow the company the opportunity to learn from SBTi’s rich experience of helping its member companies drive change and create impact on ground. Earlier this month, on the World Environment Day, Sai Life Sciences announced its renewed Sustainable Development Goals (SDG) that chart out its roadmap to achieve specific environmental, social and governance (ESG) targets by the year ending March 31, 2027. As part of the SDGs, the company has committed to reduce specific greenhouse gas emissions by 30% and replace 70% of its energy requirement with renewable sources. Previously, as part of it first edition of SDGs for the period 2019 to 2022, the company exceeded its targets in areas such as the utilization of renewable energy, recycling of hazardous waste and reduction in greenhouse gas emissions, despite significantly expanding its operations. In recent years, Sai Life Sciences has made significant investments and progress in advancing its Sustainability agenda as part of its organizational transformation initiative, Sai Nxt. Some of the notable highlights:
Became the first India-headquartered company to join the PSCI membership. Joined ACS Green Chemistry Institute Pharmaceutical Roundtable (ACS-GCIPR) as an ‘Associate Member’. Publishing annual sustainability reports since 2020. Won several prestigious awards for excellence in EHS practices and energy management. About Sai Life Sciences:
Sai Life Sciences is a full-service CRO-CDMO that works with innovator pharma and biotech companies globally, to accelerate the discovery, development, and commercialisation of complex small molecules. The company has over 2,600 employees across its facilities in India, UK and USA. Sai Life Sciences is privately held and backed by global investors, TPG Capital and HBM Healthcare Investments. https://www.sailife.com/
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f57b0c6f-4495-460f-9c80-21a291fce69b

Sai Life Sciences joins Science Based Targets initiative (SBTi), commits to fight climate change with Science

Back to video
HYDERABAD, India, June 22, 2023 (GLOBE NEWSWIRE) — To help combat climate change, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO) , announced joining Science Based Targets initiative (SBTi), a global body enabling businesses to set ambitious emission reduction targets in line with the latest climate science. Advertisement 2
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada. Exclusive articles by Kevin Carmichael, Victoria Wells, Jake Edmiston, Gabriel Friedman and others. Daily content from Financial Times, the world's leading global business publication. Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada. Exclusive articles by Kevin Carmichael, Victoria Wells, Jake Edmiston, Gabriel Friedman and others. Daily content from Financial Times, the world's leading global business publication. Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account. National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword. REGISTER TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. or
Article content
Financial Post Top Stories
Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.
Email Address
Sign Up
By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails or any newsletter. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300
Thanks for signing up! A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Financial Post Top Stories will soon be in your inbox. We encountered an issue signing you up. Please try again
Article content
Accordingly, it has committed to set near-term company-wide emission reductions in line with climate science with the SBTi. These are 5-10-year GHG (Greenhouse gas) mitigation targets in accordance with the Paris Agreement’s aim to limit global temperature rise to 1.5°C to avoid the catastrophic impacts of climate change. Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “Sai Life Sciences has joined the SBTi to address a collective imperative. The association will help in sharpening our approach to assess the impact of climate change and develop a strategy to address it. It will also strengthen our ability to nurture an organizational culture, where each employee is mindful of every act and its impact on the environment.”
Article content
Article content
Joining the SBTi will enable Sai Life Sciences to set targets, assess progress and calibrate actions to meet its goals in a time-bound manner. It will allow the company the opportunity to learn from SBTi’s rich experience of helping its member companies drive change and create impact on ground. Earlier this month, on the World Environment Day, Sai Life Sciences announced its renewed Sustainable Development Goals (SDG) that chart out its roadmap to achieve specific environmental, social and governance (ESG) targets by the year ending March 31, 2027. As part of the SDGs, the company has committed to reduce specific greenhouse gas emissions by 30% and replace 70% of its energy requirement with renewable sources. Previously, as part of it first edition of SDGs for the period 2019 to 2022, the company exceeded its targets in areas such as the utilization of renewable energy, recycling of hazardous waste and reduction in greenhouse gas emissions, despite significantly expanding its operations. Advertisement 4
Article content
In recent years, Sai Life Sciences has made significant investments and progress in advancing its Sustainability agenda as part of its organizational transformation initiative, Sai Nxt. Some of the notable highlights:
Became the first India-headquartered company to join the PSCI membership. Joined ACS Green Chemistry Institute Pharmaceutical Roundtable (ACS-GCIPR) as an ‘Associate Member’. Publishing annual sustainability reports since 2020. Won several prestigious awards for excellence in EHS practices and energy management. About Sai Life Sciences:
Sai Life Sciences is a full-service CRO-CDMO that works with innovator pharma and biotech companies globally, to accelerate the discovery, development, and commercialisation of complex small molecules. The company has over 2,600 employees across its facilities in India, UK and USA. Sai Life Sciences is privately held and backed by global investors, TPG Capital and HBM Healthcare Investments. https://www.sailife.com/
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f57b0c6f-4495-460f-9c80-21a291fce69b

Dassault Systemes (EPA: DSY) provides third-dimensional (3D) design, engineering, and product lifecycle management (PLM) software. It helps businesses to improve their design, engineering, and manufacturing processes. The company provides solutions for a wide range of industries including aerospace and defense, architecture, engineering, construction, consumer goods, retail, and more. It was founded in 1981 and is based in Velizy-Villacoublay, France.

Dassault Systemes

The integration of Dassault Systemes ` ONE Lab ' empowers us to drive productivity , enhance data quality , and fortify data security , revolutionizing our approach to research across the entire spectrum from early-stage development to commercial manufacturing '' , said Dr. Damodharen , Chief Quality Officer , Sai Life Sciences .

Science Based Targets initiative (SBTi) promotes practice in emissions reduction. It helps companies to set emission reduction targets in line with climate science and Paris Agreement goals. It serves aluminum, apparel, footwear, aviation, chemicals, and financial sectors. The company was founded in 2015 and is based in London, United Kingdom.

Science Based Targets

NIIT Foundation is a nonprofit education society. Its mission is to positively impact the underprivileged in the country through educational initiatives and employability skills development programs. The society was founded in 2004 and is based in New Delhi, India.

NIIT Foundation

Schrodinger (NASDAQ: SDGR) operates as a physics-based computational platform for drug discovery and materials research. The company's main offerings include a digital chemistry platform that uses physics and machine learning to facilitate molecular design, as well as software solutions for small molecule drug discovery, biologics drug discovery, and materials science. Schrodinger primarily serves the pharmaceutical and biotechnology industries, as well as the materials research sector. The company was founded in 1990 and is based in New York, New York.

Schrodinger

Curio Wellness operates a medical cannabis brand to provide a solution for health complications. The platform aids in increasing the accessibility of therapeutic and medicative cannabis, provides premium products, and holds educational events, and health services provided by trained staff. The company was founded in 2014 and is based in Towson, Maryland.

Curio Wellness

Wockhardt

Reliance Retail

VIP Industries

Private Equity

Sai Life Sciences focuses on pharmaceuticals and biotechnology services. The company provides services such as synthetic, medicinal, and process chemistry and is further augmented by a suite of preclinical support services including drug metabolism and pharmacokinetics, toxicology, and formulation. The company was founded in 1999 and is based in Telangana, India.

Wells Fargo Success Story

Professional Services

Platform Overview

Compare Hill Top Research vs Sai Life Sciences

Customers evaluate the quality of Hill Top Research's products using the following success metrics.